EIF2AK3 and hepatocellular carcinoma: An example of tumor response to sorafenib is shown in a 59-year-old man with recurrent HCC, who only possessed pERK+/pAkt− CTCs and had several tumor nodules with gadolinium-DTPA enhancement located in both the left and right lobes; after treatment with sorafenib for 8 mo, these tumors were shrunken or had completely disappeared as evidenced by dynamic contrast-enhanced MRI (Fig. 3A).